Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies
March 2, 2022 8:08 AM ESTJefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $90.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "Q4 Caplyta sales in mostly schizophrenia (SCZ) grew by +18% Q/Q to $25.5M (in line vs cons;... More
